Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:04:33·⟳ 抓取 20:06:18 +1m45s·⚡ 决策 10-08 20:08:17 +1m59s·19.2 天前
Scholar Rock重新向EMA提交SMA疗法apitegromab上市申请
消息方向明确为正面，且盘前尚未明显上涨，但该事件只是恢复欧盟审评流程，CHMP结论要到2027年上半年，短期盈利贡献不可量化；在缺乏高质量对齐先例且股价处于下行轨迹时，追涨的风险收益比不足。
📄 原文Investing.com↗ 原文
Scholar Rock resubmits EU application for SMA treatment
By Investing.com Advertisement Advertisement Scholar Rock resubmits EU application for SMA treatment Company News Publi…
不做 Scholar Rock Holding Corporation（SRRK.US）
重新提交欧盟申请是预期中的程序性修复而非获批，CHMP意见在2027年上半年，短期收入无法量化；叠加股价下行、FDA批准后承接偏弱和先例不足，风险收益比不支持新开多仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Scholar Rock用已支持FDA批准的替代场地重启欧盟MAA，修复了此前Catalent工厂导致的审评中断；不过这只是程序性进展而非获批，欧洲销售兑现遥远，不能形成足够的短线正期望。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
消息传播链
- 报道称Scholar Rock当日宣布重新提交欧盟MAA，并解释新场地、时间表和供货准备。市场反应:美东08:03盘前价约42.00美元，较参考收盘小幅下跌约0.47%，成交量仅181股。
关键理由
- 替代场地近期通过FDA和EMA检查且已有药瓶备货，降低了此前Catalent GMP问题继续阻断欧盟路径的风险。
- 盘前价格尚未对该消息明显重定价，说明若市场重新认可欧盟期权，理论上存在修复空间。
主要风险
- EMA受理、现场核查或CHMP审评仍可能提出额外生产、质量或临床要求，且最终意见预计迟至2027年上半年。
- SRRK近20个交易日累计下跌约22.74%，13周轨迹明显下行，弱势趋势中程序性利好可能缺乏持续买盘。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-07 · 影响 weakens
Muscular Dystrophy UK称apitegromab不会在英国提交批准，提示欧洲商业覆盖和区域策略并非全无保留。
检索:Scholar Rock apitegromab UK not submitted approval Europe risk October 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-09-23 · 影响 weakens
FDA批准后，SRRK在2026年9月14日下跌6.42%，且随后20日累计下跌约22.74%，显示重大正面监管消息后买盘承接偏弱。
检索:SRRK FDA approval September 11 2026 subsequent stock performance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不设定交易性多头仓位，避免在长期、程序性且短期无法量化收入的催化上承担趋势逆风。
方向:未找到可核验首发时间、同市场同机制且与本次相位一致的EMA重新提交先例，不能凭泛化的生物医药监管经验判断胜率。
涨幅量级:没有高质量对齐先例支撑止盈幅度；SRRK自身FDA批准后的9月14日股价下跌更提示利好兑现反应存在不确定性，但该事件机制不同，不能直接作为幅度基准。
形态:现有证据不足以证明EMA重新提交类事件会反复高开低走，但公司近期弱势和卖消息现象构成风险。
工具执行结果 · 成功 8 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 61 ms
{"result": "search_processed_events:agent query=`apitegromab alternate fill-finish facility catalent indiana ema | scholar rock apitegromab eu maa resubmission ema | srrk resubmits marketing authorisation application sma europe`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent - fetch_decision_experience 成功 stock_tools HTTP · 10 ms
{ - stock_quote 成功 stock_tools HTTP · 247 ms
{ - web_search 成功 doubao_search · 3,177 ms
豆包搜索结果（原始查询:Scholar Rock apitegromab resubmitted Marketing Authorisation Application EMA press release October 2026；API SearchType:web） - web_search 成功 doubao_search · 2,013 ms
豆包搜索结果（原始查询:Scholar Rock withdraws apitegromab EU MAA Catalent Indiana GMP August 2026；API SearchType:web） - search_case_library 成功 stock_tools HTTP · 22 ms
{"result": "search_case_library「SRRK.US」—— 与这些标的相关的自家决策案例(本页 10 条,该标的全历史相关记录共 11 条；ENTER 只按该标的自己的腿统计):\n◆ SRRK.US：相关历史决策 11 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 10 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-08-21 UTC(CST 2026-08-22) 不做 · 事件:S - kb_search 失败 stock_tools HTTP · 59 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 3,880 ms
豆包搜索结果（原始查询:biotech stock reaction EMA MAA resubmitted after manufacturing withdrawal fill finish facility stock rose；API SearchType:web） - web_search 成功 doubao_search · 3,766 ms
豆包搜索结果（原始查询:Scholar Rock FDA approval apitegromab September 11 2026 stock reaction SRRK；API SearchType:web）
原文全文
展开原文 · 7,467 字
Scholar Rock resubmits EU application for SMA treatment By Investing.com
Advertisement
Advertisement
Scholar Rock resubmits EU application for SMA treatment
Company News
Published
Oct 08, 2026, 08:04 AM
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
© Reuters
In this article:
SRRK
-0.59%
CAMBRIDGE, Mass. -
Scholar Rock
(
NASDAQ:SRRK
) announced today it has resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency for the treatment of children and adults with spinal muscular atrophy.
The resubmitted application includes an alternate fill-finish facility in place of the Catalent Indiana facility, according to a press release statement. The alternate facility is the same site that supported the U.S. Food and Drug Administration approval of ISEMBYLD (apitegromab-mstn) on September 11, 2026.
In August 2026, Scholar Rock withdrew its previous application after informing the Committee for Medicinal Products for Human Use of a lack of GMP compliance at the Catalent Indiana fill-finish facility. The company anticipates a CHMP opinion in the first half of 2027.
The alternate fill-finish facility is a U.S.-based site producing multiple commercial products with recent FDA and EMA inspections, the company stated. Supply from this facility is available, with vials on site at a third-party provider awaiting packaging and labeling for commercialization upon approval from the European Commission.
Apitegromab is a monoclonal antibody that inhibits myostatin activation by binding to pro- and latent forms of myostatin in skeletal muscle. In the Phase 3 SAPPHIRE study, individuals receiving apitegromab demonstrated motor function improvement after one year of treatment while those on an SMN2-targeted treatment alone experienced a loss of motor function.
The FDA approved apitegromab under the brand name ISEMBYLD in the United States in September 2026 for the treatment of SMA in adults and pediatric patients 2 years of age and older who are currently receiving a SMN2-targeted treatment. The EMA has granted Priority Medicines and Orphan Medicinal Product designations to apitegromab for SMA treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,809.10
-370.1
-0.72%
US 500
7,769.50
-32.2
-0.41%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.69
+0.61
+4.05%
Dollar Index
102.17
+0.157
+0.15%
Crude Oil WTI Futures
92.28
+4.00
+4.53%
Brent Oil Futures
104.71
+4.51
+4.50%
Natural Gas Futures
3.269
+0.066
+2.06%
Gold Futures
4,150.47
+9.77
+0.24%
Silver Futures
59.178
-1.116
-1.85%
Copper Futures
6.6453
-0.0042
-0.06%
US Soybeans Futures
1,294.50
-2.50
-0.19%
U.S. 10Y
5.331
+0.053
+1.00%
U.S. 30Y
5.702
+0.041
+0.72%
U.S. 5Y
5.075
+0.054
+1.08%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.14
-0.34
-0.33%
Euro Bund Futures
120.64
-0.17
-0.14%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Scholar Rock resubmits EU application for SMA treatment
Company News
Published
Oct 08, 2026, 08:04 AM
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
© Reuters
In this article:
SRRK
-0.59%
CAMBRIDGE, Mass. -
Scholar Rock
(
NASDAQ:SRRK
) announced today it has resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency for the treatment of children and adults with spinal muscular atrophy.
The resubmitted application includes an alternate fill-finish facility in place of the Catalent Indiana facility, according to a press release statement. The alternate facility is the same site that supported the U.S. Food and Drug Administration approval of ISEMBYLD (apitegromab-mstn) on September 11, 2026.
In August 2026, Scholar Rock withdrew its previous application after informing the Committee for Medicinal Products for Human Use of a lack of GMP compliance at the Catalent Indiana fill-finish facility. The company anticipates a CHMP opinion in the first half of 2027.
The alternate fill-finish facility is a U.S.-based site producing multiple commercial products with recent FDA and EMA inspections, the company stated. Supply from this facility is available, with vials on site at a third-party provider awaiting packaging and labeling for commercialization upon approval from the European Commission.
Apitegromab is a monoclonal antibody that inhibits myostatin activation by binding to pro- and latent forms of myostatin in skeletal muscle. In the Phase 3 SAPPHIRE study, individuals receiving apitegromab demonstrated motor function improvement after one year of treatment while those on an SMN2-targeted treatment alone experienced a loss of motor function.
The FDA approved apitegromab under the brand name ISEMBYLD in the United States in September 2026 for the treatment of SMA in adults and pediatric patients 2 years of age and older who are currently receiving a SMN2-targeted treatment. The EMA has granted Priority Medicines and Orphan Medicinal Product designations to apitegromab for SMA treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Scholar Rock resubmits EU application for SMA treatment
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,809.10
-370.1
-0.72%
US 500
7,769.50
-32.2
-0.41%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.69
+0.61
+4.05%
Dollar Index
102.17
+0.157
+0.15%
Crude Oil WTI Futures
92.28
+4.00
+4.53%
Brent Oil Futures
104.71
+4.51
+4.50%
Natural Gas Futures
3.269
+0.066
+2.06%
Gold Futures
4,150.47
+9.77
+0.24%
Silver Futures
59.178
-1.116
-1.85%
Copper Futures
6.6453
-0.0042
-0.06%
US Soybeans Futures
1,294.50
-2.50
-0.19%
U.S. 10Y
5.331
+0.053
+1.00%
U.S. 30Y
5.702
+0.041
+0.72%
U.S. 5Y
5.075
+0.054
+1.08%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.14
-0.34
-0.33%
Euro Bund Futures
120.64
-0.17
-0.14%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。